Essential Thrombocythemia: Diagnosis and Management
Executive Summary
Contents
- Pathophysiology and Driver Mutations
- JAK-STAT signaling
- JAK2 vs CALR vs MPL phenotype
- WHO 2022 Diagnostic Criteria and Workup
- Bone marrow morphology
- Triple-negative evaluation
- Risk Stratification and Treatment Algorithm
- IPSET-thrombosis score
- Cytoreductive selection
- Drug Therapy and Monitoring
- Complications and Special Populations
- Pearls, Pitfalls, and FAQs
S1. Pathophysiology and Driver Mutations
Essential thrombocythemia represents clonal expansion of a pluripotent hematopoietic stem cell with a phenotype dominated by megakaryocyte proliferation. The unifying biological theme across all driver mutations is constitutive activation of the JAK-STAT signaling pathway downstream of the thrombopoietin receptor (MPL), driving megakaryocyte expansion and sustained platelet overproduction independent of physiologic thrombopoietin regulation. Unlike reactive thrombocytosis - where elevated platelets reflect increased thrombopoietin from inflammation, iron deficiency, infection, or asplenia - ET features clonal hematopoiesis with abnormal megakaryocyte morphology and intrinsic stem cell autonomy.
JAK2 V617F Mutation (50-60%)
The most common driver, JAK2 V617F is a gain-of-function point mutation in exon 14 (c.1849G>T, p.Val617Phe) within the pseudokinase JH2 domain. Loss of autoinhibition produces constitutive kinase activation, hypersensitivity to thrombopoietin, and downstream STAT5/STAT3 phosphorylation. JAK2 mutation status is the strongest single molecular predictor of thrombosis in ET (relative risk 2.0-2.5 vs unmutated cases). JAK2 allele burden (typically 10-50% in ET, contrasting with >50% in polycythemia vera) correlates with phenotype - high allele burden suggests evolution toward erythrocytosis or fibrosis.
CALR Exon 9 Mutations (20-25%)
Calreticulin mutations are insertions or deletions in exon 9 producing a frameshift and a novel C-terminal peptide that aberrantly activates MPL signaling. Type 1 (52-bp deletion, c.1092_1143del) accounts for 60-70% of CALR-mutated cases; Type 2 (5-bp insertion, c.1154_1155insTTGTC) accounts for 25-35%. CALR-mutated ET features younger age at diagnosis, higher platelet counts, lower hemoglobin and leukocyte counts, and importantly lower thrombotic risk (5-year cumulative thrombosis 11% vs 25% in JAK2-mutated). Type 1 CALR carries higher risk of myelofibrotic transformation than Type 2.
MPL W515 Mutations (3-5%)
MPL gain-of-function mutations (W515L, W515K, W515A) at the transmembrane junction of the thrombopoietin receptor produce ligand-independent JAK-STAT activation. MPL-mutated ET has thrombotic risk intermediate between JAK2 and CALR, with higher rates of bone marrow fibrotic progression.
Triple-Negative ET (10-15%)
Patients without JAK2, CALR, or MPL mutations require expanded molecular evaluation - non-canonical JAK2 exon 12 mutations, MPL S505N, or rare germline thrombopoietin pathway variants may be detected by targeted sequencing panels. Triple-negative status mandates rigorous exclusion of reactive thrombocytosis (iron deficiency, occult inflammation, malignancy, post-splenectomy, hyposplenism) and warrants bone marrow biopsy in all cases. Prognosis in true triple-negative ET is generally favorable with lower thrombotic risk than JAK2-positive disease.
S2. WHO 2022 Diagnostic Criteria and Workup
WHO 2022 classification requires meeting all four major criteria OR the first three major criteria plus the minor criterion. Bone marrow biopsy is mandatory for definitive diagnosis - it cannot be omitted even when JAK2/CALR/MPL is positive, because morphologic distinction from prefibrotic primary myelofibrosis (which can also show thrombocytosis) is critical for prognosis and management.
| Criterion | Specification |
|---|---|
| Major 1 | Sustained platelet count >=450x10^9/L on >=2 occasions, separated by >=4 weeks |
| Major 2 | Bone marrow biopsy: proliferation mainly of megakaryocyte lineage with increased numbers of enlarged, mature megakaryocytes with hyperlobulated nuclei. No significant increase or left shift in granulopoiesis or erythropoiesis. Reticulin fibrosis grade 0-1 (excludes prefibrotic PMF if grade >=2) |
| Major 3 | Not meeting WHO criteria for BCR-ABL1+ CML, polycythemia vera, primary myelofibrosis, MDS, or other myeloid neoplasm |
| Major 4 | Presence of JAK2, CALR, or MPL mutation |
| Minor | Presence of clonal marker (other than JAK2/CALR/MPL) OR absence of evidence for reactive thrombocytosis |
Initial Laboratory Evaluation
The diagnostic workup begins with a comprehensive blood count, peripheral smear, ferritin and iron studies (to exclude iron deficiency-driven reactive thrombocytosis), C-reactive protein and ESR (inflammation screen), comprehensive metabolic panel including LDH (elevated in proliferative disease), and review for occult malignancy when clinically indicated. Peripheral smear in ET typically shows large, hypogranular platelets and frequent platelet anisocytosis; the white cell line is typically normal without left shift, and red cell morphology is unremarkable in early disease.
| Test | Purpose | ET Pattern |
|---|---|---|
| JAK2 V617F (allele-specific PCR) | Most common driver | Positive 50-60%; allele burden typically 10-50% |
| CALR exon 9 (sequencing or fragment analysis) | Second most common driver | Positive 20-25%; Type 1 deletion or Type 2 insertion |
| MPL W515 (sequencing) | Third driver if JAK2/CALR negative | Positive 3-5% |
| Bone marrow biopsy + reticulin stain | Mandatory for diagnosis; rule out PMF | Megakaryocytic proliferation; reticulin grade 0-1 |
| Cytogenetics (karyotype) | Exclude BCR-ABL1; baseline clonal abnormalities | Normal in 90%; abnormalities (+8, +9, del(13q)) in 5-10% |
| BCR-ABL1 by RT-PCR | Exclude CML masquerading as ET | Negative |
| Ferritin, TSAT | Exclude iron deficiency reactive thrombocytosis | Normal or elevated |
| EPO level | Differentiate from PV when borderline Hb | Normal |
S3. Risk Stratification and Treatment Algorithm
IPSET-Thrombosis Score (Revised 2012)
The IPSET-thrombosis score is the standard validated tool for stratifying thrombotic risk and selecting management intensity. Risk is calculated by summing four weighted factors: age >60 years (1 point), cardiovascular risk factors including hypertension, diabetes, hyperlipidemia, smoking (1 point), prior arterial or venous thrombosis (2 points), and JAK2 V617F mutation (2 points). The score directly maps to a treatment algorithm.
| IPSET Score | Risk Category | 10-Year Thrombosis Risk | Recommended Therapy |
|---|---|---|---|
| 0 | Very low | ~5% | Observation; aspirin only if microvascular symptoms or CV risk factors |
| 1 | Low | ~10% | Aspirin 75-100 mg PO daily |
| 2 | Intermediate | ~15-20% | Aspirin + consider hydroxyurea (especially if age >60 without JAK2) |
| >=3 | High | ~25-30% | Aspirin + cytoreduction (hydroxyurea first-line, target platelets <400x10^9/L) |
Special Situations That Override IPSET
Several clinical scenarios require treatment beyond what IPSET-thrombosis alone would dictate. Extreme thrombocytosis with platelet count >1000-1500x10^9/L mandates cytoreduction regardless of IPSET score because of acquired von Willebrand syndrome and bleeding risk. Pregnancy management requires interferon-alpha when cytoreduction is needed because hydroxyurea is teratogenic and anagrelide crosses the placenta. Patients <40 years requiring cytoreduction should preferentially receive interferon-alpha over hydroxyurea given concerns about long-term leukemogenic potential of hydroxyurea. Persistent microvascular symptoms (erythromelalgia, transient ischemic events, headaches) on once-daily aspirin may require BID dosing due to accelerated platelet turnover.
S4. Drug Therapy and Monitoring
Antiplatelet Therapy
Low-dose aspirin 75-100 mg PO daily is the cornerstone of antithrombotic prophylaxis for IPSET intermediate, low (with cardiovascular risk factors), or high-risk ET. CALR-mutated very-low-risk patients without cardiovascular risk factors may not benefit from aspirin and may have increased bleeding - withhold unless microvascular symptoms develop. Twice-daily aspirin 75-100 mg PO BID may be considered for persistent microvascular symptoms despite once-daily dosing because the supranormal platelet turnover in ET shortens the effective antiplatelet duration of single daily dose.
Cytoreduction - First Line
Hydroxyurea (Hydrea) is first-line cytoreduction for high-risk ET in patients >40 years. Starting dose 500-1000 mg PO daily, typically titrated upward by 500 mg every 1-2 weeks based on platelet response, with maximum dose 2000-3000 mg PO daily. Target platelet count <400x10^9/L without inducing significant cytopenias (target neutrophils >1.0x10^9/L, hemoglobin >10 g/dL). Monitor CBC weekly during titration, then every 2-4 weeks once stable, then every 3 months for maintenance. Adverse effects include macrocytosis (universal and benign), oral and lower extremity ulcers (10-15%), painful leg ulcers (mandate discontinuation), nail discoloration, fevers, gastrointestinal upset, and a theoretical concern for leukemogenicity (controversial; absolute risk increase if any is small).
Cytoreduction - Alternatives
Interferon-alpha (pegylated, ropeginterferon) is preferred for patients <40 years, in pregnancy, and for hydroxyurea-intolerant or resistant disease. Pegylated interferon-alpha-2a 45-180 mcg SC weekly or ropeginterferon alfa-2b 100-500 mcg SC q2 weeks. Interferon achieves molecular responses (decreased JAK2 allele burden) in 30-50% of patients. Adverse effects include flu-like symptoms (75% initially, tolerance develops), depression and neuropsychiatric symptoms (mandate discontinuation if severe), elevated transaminases, autoimmune disorders (thyroid 5-10%), and injection site reactions.
Anagrelide (Agrylin) is second-line cytoreduction acting via inhibition of megakaryocyte differentiation. Starting dose 0.5 mg PO BID titrated to 1.5-2 mg PO BID max. Particularly useful when leukocyte and erythrocyte lines need preservation but is associated with increased rates of myelofibrotic transformation, fluid retention, headaches, palpitations and tachyarrhythmias (avoid in cardiac disease), and gastrointestinal upset. PT-1 trial showed inferior arterial thrombosis prevention vs hydroxyurea in JAK2-mutated ET.
Ruxolitinib (Jakafi) is reserved for hydroxyurea-resistant or intolerant disease per the MAJIC-ET trial. Starting dose 10 mg PO BID titrated to platelet response. Reserve for symptomatic patients failing standard cytoreduction; not first-line in ET (unlike myelofibrosis where it is foundational).
| Drug | Indication | Dose | Key Monitoring |
|---|---|---|---|
| Aspirin | Antithrombotic prophylaxis | 75-100 mg PO daily (BID for refractory microvascular symptoms) | Bleeding history; withhold if plt >1000-1500 |
| Hydroxyurea | 1st-line cytoreduction (age >40) | 500-3000 mg PO daily; target plt <400x10^9/L | CBC weekly during titration; skin/leg exam; mucositis |
| Pegylated IFN-alpha-2a | Pregnancy, age <40, HU intolerant | 45-180 mcg SC weekly | LFT, TSH, CBC monthly; psychiatric screen |
| Ropeginterferon alfa-2b | 2nd-generation IFN; longer interval | 100-500 mcg SC q2 weeks | Same as PEG-IFN |
| Anagrelide | 2nd-line; preserve other cell lines | 0.5-2 mg PO BID | ECG, fluid status; avoid in cardiac disease |
| Ruxolitinib | HU-resistant or intolerant | 10 mg PO BID; titrate | CBC; varicella zoster reactivation |
Hydroxyurea Resistance/Intolerance Definitions (ELN Criteria)
Resistance is defined by any of: platelet count >600x10^9/L after 3 months of >=2 g/day; platelet count >400x10^9/L with WBC <2.5x10^9/L or Hb <10 g/dL at any dose; or thrombosis or bleeding while on hydroxyurea. Intolerance includes: ANC <1.0x10^9/L, platelet <100x10^9/L, or Hb <10 g/dL at lowest hydroxyurea dose required for adequate response; presence of leg ulcers or other unacceptable mucocutaneous toxicity; hydroxyurea-related fever. Documented resistance or intolerance triggers switch to interferon-alpha or anagrelide.
S5. Complications and Special Populations
Thrombotic Complications
Thrombosis is the leading cause of morbidity in ET. Arterial events (60-70% of thrombotic complications) include cerebrovascular events (TIA, stroke), myocardial infarction, peripheral arterial occlusion, and microvascular events (erythromelalgia, ocular ischemia). Venous events (30-40%) include deep vein thrombosis, pulmonary embolism, and the highly characteristic splanchnic vein thrombosis (Budd-Chiari, portal vein thrombosis, mesenteric vein thrombosis) - any unexplained splanchnic thrombosis mandates JAK2 V617F testing as ET or PV may be the underlying cause in 30-50% of cases. Following any thrombotic event, indefinite anticoagulation is generally recommended in addition to cytoreduction.
Hemorrhagic Complications and Acquired von Willebrand Syndrome
Bleeding affects 5-10% of ET patients lifetime, predominantly when platelet counts exceed 1000x10^9/L through acquired von Willebrand syndrome (AvWS). Mechanism: massive platelet surface area adsorbs and proteolyzes high-molecular-weight von Willebrand factor multimers, producing functional vWF deficiency despite normal vWF antigen levels. Diagnosis: vWF:RCo/vWF:Ag ratio <0.7, decreased ristocetin cofactor activity, absent HMW multimers on gel electrophoresis. Management: hold aspirin until platelet count drops below 1000x10^9/L; urgent cytoreduction with hydroxyurea (preferred) or anagrelide; perioperative DDAVP 0.3 mcg/kg IV or vWF concentrate for active bleeding.
Disease Transformation
Two principal long-term outcomes: post-ET myelofibrosis (4-11% at 15 years) presenting with progressive splenomegaly, cytopenias, constitutional symptoms, and bone marrow fibrosis (reticulin grade >=2); and acute leukemic transformation (1-3% at 10 years), more common with prior alkylator exposure (busulfan, pipobroman) and possibly with hydroxyurea after long exposure. Transformation risk is higher in CALR Type 1 (myelofibrosis) and triple-negative or unfavorable karyotype patients (leukemia).
Pregnancy Management
ET pregnancies carry 30-50% risk of fetal loss (predominantly first-trimester) and 5-10% risk of placental thrombosis, abruption, or pre-eclampsia. Management: low-dose aspirin 75-100 mg PO daily throughout pregnancy unless contraindicated; LMWH prophylaxis for high-risk patients (prior thrombosis, prior pregnancy loss) with enoxaparin 40 mg SC daily antepartum, increased to therapeutic dose 1 mg/kg SC q12h postpartum for 6 weeks. Cytoreduction with pegylated interferon-alpha 45-90 mcg SC weekly is the only safe agent in pregnancy - hydroxyurea and anagrelide are contraindicated. Discontinue aspirin 1 week before delivery and restart 12-24 hours postpartum if hemostasis is secure.
Perioperative Management
Pre-procedure platelet target <400x10^9/L for major surgery. Continue aspirin through procedures with low bleeding risk; hold 5-7 days before high-bleeding-risk surgery (intracranial, ophthalmic, posterior chamber spinal). For VTE prophylaxis postoperatively, mechanical (sequential compression) plus pharmacologic with LMWH enoxaparin 40 mg SC daily until full mobilization. For active bleeding or vWS during surgery, consider platelet apheresis to reduce platelets emergently.
S7. Practice Insights: Bedside Notes on Essential Thrombocythemia
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)A platelet count flagged on a pre-operative panel in an otherwise well patient is how most essential thrombocythemia is found, and from there ET management lives or dies by IPSET-thrombosis risk stratification and recognizing the paradox of bleeding at very high platelet counts. In experienced hands the pivot points are confirming clonal driver mutation BEFORE committing to ET diagnosis, applying IPSET-thrombosis to drive therapy, and checking ristocetin cofactor activity at platelet counts >1000-1500k before reaching for aspirin. Experienced practice tracks three things at every visit: platelet count, JAK2 V617F allele burden (predicts risk), and any bleeding/thrombosis events.
What the Guideline Misses — Rule Out Reactive Thrombocytosis First
Reactive thrombocytosis is FAR more common than ET — iron deficiency, infection, inflammation, malignancy. In experienced practice every isolated thrombocytosis gets ferritin + CRP + cancer-appropriate workup BEFORE BM biopsy. About 1 in 3 of the "suspected ET" referrals turn out to be reactive thrombocytosis — most often unrecognized iron deficiency in menstruating women.
Patterns Experienced Clinicians Have Seen Repeat — Splanchnic Thrombosis Presentation
Like polycythemia vera, ET can present with splanchnic vein thrombosis. In practice any unprovoked Budd-Chiari, portal vein thrombosis, or mesenteric vein thrombosis gets JAK2 V617F + CALR + MPL testing even with normal CBC (hypersplenism masks). About 1 in 6 of the splanchnic thromboses turn out to be MPN-driven — half PV, half ET.
Cytoreduction Choice
High-risk ET (age >60 + JAK2+, OR prior thrombosis, OR symptomatic disease) needs cytoreduction. Hydroxyurea is the standard for elderly. Pegylated interferon alfa-2a (ropeginterferon if available) for patients under 60 — particularly considering reproductive plans (interferon doesn't impair fertility, hydroxyurea is teratogenic). Anagrelide as alternative for HU-intolerant, particularly useful in pregnancy.
Bedside Heuristic — Don't Aspirin Extreme Platelet Counts
Acquired von Willebrand syndrome develops at platelet counts >1000-1500k from excessive cleavage of large VWF multimers by abundant platelets. Aspirin in this setting causes major bleeding. In practice experienced clinicians check ristocetin cofactor activity before starting aspirin in any patient with platelets >1000k; if <30%, they withhold aspirin until cytoreduction lowers platelets to safer range.
A Case That Reframed the established Approach — Aspirin-Induced Bleeding at Platelet 1800k
A woman in her late 50s with newly diagnosed ET (platelets 1800k, JAK2 V617F positive) was started on aspirin 81 mg daily by referring team as "low-dose thromboprophylaxis." Two weeks later she presented with GI bleeding and epistaxis — Hgb dropped from 13 to 8. The treating clinicians checked ristocetin cofactor activity: 18% (low). Diagnosis: acquired von Willebrand syndrome from extreme platelet count. Stopped aspirin, started hydroxyurea aggressive titration. Within 3 weeks platelets dropped to 600k, VWF activity normalized to 75%, bleeding resolved. Restarted aspirin safely. What experienced clinicians learned: extreme thrombocytosis is a PARADOXICAL bleeding state, not a thrombotic state. Check VWF activity before aspirin at platelets >1000k.
Practice Pattern Refinements That Diverge From Standard Guidelines
- Reactive thrombocytosis workup before BM biopsy on every "ET suspect." Ferritin (iron deficiency very common), CRP/ESR (inflammation), age-appropriate cancer screen. Saves invasive workup in ~1 in 3.
- JAK2 + CALR + MPL on every unprovoked splanchnic thrombosis even with "normal" CBC. Hypersplenism masks counts in acute splanchnic thrombosis. ~1 in 6 reveal MPN.
- Ristocetin cofactor activity before aspirin at platelets >1000k. If <30%, withhold aspirin until cytoreduction lowers platelets. Aspirin in acquired VWS causes hemorrhage, not thromboprophylaxis.
- IPSET-thrombosis risk stratification drives every treatment decision. Score: age >60 (1), CV risk (1), thrombosis hx (2), JAK2 (2). Very low/low → aspirin only. Intermediate → aspirin. High → aspirin + cytoreduction. Hydroxyurea for elderly, peg-IFN for <60 (especially reproductive plans), anagrelide as alternative.
S6. Pearls, Pitfalls, and FAQs
Pearl 1: Always test JAK2 in unexplained splanchnic vein thrombosis
Up to 30-50% of patients with portal, mesenteric, hepatic, or splenic vein thrombosis without obvious provoking cause have an underlying MPN, often ET or PV. JAK2 V617F testing should be performed even when peripheral blood counts are normal because splenomegaly and portal hypertension can mask the typical hematologic abnormalities through hypersplenism. Molecular diagnosis here changes anticoagulation duration to indefinite and triggers cytoreduction.
Pitfall 1: Treating reactive thrombocytosis as ET
Reactive thrombocytosis from iron deficiency, occult infection, inflammatory disease, post-splenectomy, or malignancy can drive platelets >1000x10^9/L without conferring thrombotic risk. Driver mutation testing is the discriminator - reactive thrombocytosis is JAK2/CALR/MPL negative. Misdiagnosing reactive thrombocytosis as ET subjects patients to unnecessary lifelong cytoreduction. Always check ferritin and CRP at minimum before invoking ET diagnosis.
Pearl 2: CALR-mutated ET has lower thrombotic risk than JAK2-mutated
5-year cumulative thrombosis is 11% in CALR-mutated ET vs 25% in JAK2-mutated ET. This is reflected in IPSET-thrombosis where JAK2 mutation alone contributes 2 points - CALR/MPL/triple-negative cases without other risk factors fall into very-low or low-risk categories where aspirin alone or even observation may be appropriate. Don't reflexively apply hydroxyurea to age >60 CALR patients without other risk factors - the IPSET score may not warrant it.
Pitfall 2: Stopping aspirin during procedures without considering thrombosis risk
Routine aspirin discontinuation 7 days before any procedure exposes ET patients to acute thrombotic events during the perioperative period when prothrombotic factors are heightened. Aspirin should be continued through procedures with low bleeding risk (cataract surgery, dental cleaning, skin biopsies). Hold only for high-bleeding-risk surgery, and restart within 24 hours of secure hemostasis. Never indefinitely discontinue aspirin in IPSET intermediate or high-risk ET.
Pearl 3: Microvascular symptoms predict aspirin response
Erythromelalgia (burning, erythema of palms and soles), transient visual disturbances, headaches, paresthesias, and atypical chest pain in ET reflect platelet-mediated microcirculatory dysfunction. These symptoms typically resolve within hours of starting low-dose aspirin and recur within hours of missing a dose. Persistence on once-daily aspirin warrants BID dosing because of accelerated platelet turnover - the antiplatelet effect of a single aspirin dose lasts <24 hours in ET unlike normal subjects.
Pitfall 3: Skipping bone marrow biopsy in JAK2-positive thrombocytosis
Although JAK2 V617F satisfies WHO 2022 Major Criterion 4 for ET, bone marrow biopsy remains mandatory because JAK2 is also positive in polycythemia vera (95%), prefibrotic primary myelofibrosis, and post-ET myelofibrosis. Distinguishing ET from prefibrotic PMF is prognostically critical - prefibrotic PMF has 3-5x higher transformation risk and earlier mortality. Hematology consultation with expert hematopathology review of marrow morphology is essential, not optional.
Frequently Asked Questions
- Paroxysmal Nocturnal Hemoglobinuria: Diagnosis, Eculizumab, and Pegcetacoplan
- Marginal Zone Lymphoma: MALT, Splenic, and Nodal Subtypes — Diagnosis and Management
- Thalassemia Alpha and Beta: Genetic Basis, Diagnosis, and Transfusion-Iron Chelation Management
- Polycythemia Vera: Diagnosis and Management
- Hereditary Spherocytosis: Diagnosis, Severity, and Splenectomy Decisions
- Immune Thrombocytopenia: Diagnosis, First-Line Therapy, and TPO Receptor Agonists